CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: To begin we measured, by flow cytometry, the proportion of CD34+/CD26+ cells in 31 bone marrow samples from 20 CML patients, at diagnosis and during treatment with imatinib.